<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04419779</url>
  </required_header>
  <id_info>
    <org_study_id>C-00044</org_study_id>
    <nct_id>NCT04419779</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes on Insulin Therapy</brief_title>
  <acronym>REVITA-T2Di</acronym>
  <official_title>A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes on Insulin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fractyl Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fractyl Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Revita® system is being investigated to assess the efficacy of DMR versus Sham on&#xD;
      improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2&#xD;
      Diabetes who are inadequately controlled with insulin therapy. The purpose of this study is&#xD;
      to demonstrate the efficacy and safety of the Fractyl DMR Procedure using the Revita® System&#xD;
      compared to a sham. Subjects randomized to the DMR procedure will be followed per protocol&#xD;
      till 48 weeks post treatment. Subjects in the Sham treatment arm will be offered cross over&#xD;
      to receive the DMR treatment at 48 weeks and will be followed per protocol for 24 weeks post&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the percentage of subjects at Week 24 who achieve a HbA1c of &lt;/= 7.0% without the need for insulin, DMR vs Sham</measure>
    <time_frame>24 Weeks</time_frame>
    <description>The primary endpoint will be analyzed using a logistic regression model with terms for baseline insulin dose, baseline HbA1c, change from screening to baseline HbA1c, region (e.g. USA, OUS), baseline FPG, and treatment group.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">428</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Duodenal Mucosal Resurfacing (DMR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal muscosa in an upper endoscopic procedure in patients with type 2 diabetes on insulin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duodenal Mucosal Resurfacing Sham (Sham)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with type 2 diabetes on insulin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Duodenal Mucosal Resurfacing (DMR)</intervention_name>
    <description>The Fractyl DMR Procedure utilizes the Revita® Catheter to perform hydrothermal ablation of the duodenum. The Catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-musical space, followed by an ablation of the duodenal mucosa. Subjects who receive the DMR treatment are followed for 48 weeks post treatment.</description>
    <arm_group_label>Duodenal Mucosal Resurfacing (DMR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Duodenal Mucosal Resurfacing (Sham)</intervention_name>
    <description>The Sham procedure consists of placing the Revita® Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient. Subjects who receive the Sham procedure are followed for 48 weeks post treatment and are offered cross over to undergo the DMR procedure at 48 weeks and are followed for further 24 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.</description>
    <arm_group_label>Duodenal Mucosal Resurfacing Sham (Sham)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male; and Non-pregnant, Non-lactating Females&#xD;
&#xD;
          2. Age between 21 and 70 years (both inclusive)&#xD;
&#xD;
          3. Subjects with type 2 diabetes on stable doses of metformin (maximum tolerated dose)&#xD;
             requiring a minimum of 20 units up to a maximum of 60 units of basal insulin; OR&#xD;
             Subjects currently on basal insulin (20-60 units/day) who meet other inclusion&#xD;
             criteria but are on other ADAs (including GLP-1a, DPP4, etc) are eligible following an&#xD;
             8-week washout period and initiating on Metformin if not already on it.&#xD;
&#xD;
          4. Glycosylated Hemoglobin A1c (HbA1c) of 7.5-9.5% (both inclusive) confirmed at the end&#xD;
             of at least 3-week stable run in period.&#xD;
&#xD;
          5. FPG ≥180 to &lt;270 mg/dl (measured after overnight 8 hr fasting and at least 36 hours&#xD;
             after the last evening dose of glargine or at least 12 hours after the last dose of&#xD;
             NPH insulin)&#xD;
&#xD;
          6. Body Mass Index (BMI) ≥ 28 and ≤ 40 kg/m2&#xD;
&#xD;
          7. Women of Child-bearing potential (WOCBP) should have negative urine beta hCG pregnancy&#xD;
             test and must agree to use two of the established contraceptive methods throughout the&#xD;
             study duration&#xD;
&#xD;
          8. Able to sign an informed consent form and comply with study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HbA1c &lt;7.5 or &gt;9.5% and/or &lt;180mg or FPG ≥ 270 mg/dl, confirmed by laboratory&#xD;
             measurement, after overnight 8hr fasting (off insulin) after at least 3 weeks stable&#xD;
             run-in period.&#xD;
&#xD;
          2. Known case of absolute insulin deficiency as indicated by clinical assessment, and a&#xD;
             fasting plasma C-peptide of &lt;0.6 ng/ml&#xD;
&#xD;
          3. Any drugs or concomitant medications (such as psychoactive drugs such as&#xD;
             carbamazepine, phenobarbital, sympathomimetics, corticosteroids and sex hormones,&#xD;
             etc.) that can interfere with glucose metabolism&#xD;
&#xD;
          4. Subjects who have a known or documented SGLT2i and/or Metformin intolerance prior to&#xD;
             the study&#xD;
&#xD;
          5. Recurrent or severe urinary tract or genital mycotic infections or history of&#xD;
             genitourinary infection within 4 weeks prior to informed consent&#xD;
&#xD;
          6. ALT &gt;3 times upper limit normal values unless the findings are consistent with&#xD;
             Gilberts disease or if associated with underlying NAFLD.&#xD;
&#xD;
          7. Use of an investigational drug within 1 month or 5 half-lives (whichever is longer)&#xD;
             before the screening&#xD;
&#xD;
          8. Diagnosed with Type 1 Diabetes or with a recent history of ketoacidosis&#xD;
&#xD;
          9. Ketosis-prone Type 2 Diabetes&#xD;
&#xD;
         10. History of non healing diabetic ulcers or amputations&#xD;
&#xD;
         11. History of more than 1 severe hypoglycemia episode or unawareness within past 6 months&#xD;
             of screening&#xD;
&#xD;
         12. Known intestinal autoimmune disease, as evidenced by either a positive Anti-GAD test,&#xD;
             including Celiac disease, or pre-existing symptoms of lupus erythematosus, scleroderma&#xD;
             or other autoimmune connective tissue disorder, which affects the small intestine&#xD;
&#xD;
         13. Secondary hypothyroidism or inadequately controlled primary hypothyroidism (TSH value&#xD;
             outside the normal range at screening)&#xD;
&#xD;
         14. Known history of thyroid cancer or hyperthyroidism who have undergone treatment within&#xD;
             past 12 months or inadequately controlled hyperthyroidism&#xD;
&#xD;
         15. An uncontrolled endocrine condition such as multiple endocrine neoplasia etc (except&#xD;
             type 2 diabetes)&#xD;
&#xD;
         16. Known history of a structural or functional disorder of the esophagus, including any&#xD;
             swallowing disorder, esophageal chest pain disorders, or drug-refractory esophageal&#xD;
             reflux symptoms, active and uncontrolled GERD (grade 3 esophagitis or greater)&#xD;
&#xD;
         17. Known history of a structural or functional disorder of the stomach, including gastric&#xD;
             ulcer, chronic gastritis, gastric varices, (a large hiatal hernia or type II and&#xD;
             higher paraoesophageal hernia) cancer or any other disorder of the stomach&#xD;
&#xD;
         18. Previous GI surgery that could affect the ability to treat the duodenum such as&#xD;
             subjects who have had a Billroth 2, Roux-en-Y gastric bypass, gastric sleeve or other&#xD;
             similar procedures or conditions&#xD;
&#xD;
         19. Known history of chronic pancreatitis or a recent history of acute pancreatitis within&#xD;
             the past year&#xD;
&#xD;
         20. Presence of acute or chronic Hepatitis B or C (except if Hep C is cured) of Cirrhosis;&#xD;
             or hepatic decompensation/acute liver disease during the last 6 months; or alcoholic&#xD;
             or autoimmune chronic hepatitis.&#xD;
&#xD;
         21. Symptomatic gallstones or symptomatic kidney stones, acute cholecystitis&#xD;
&#xD;
         22. Clinically active systemic infection&#xD;
&#xD;
         23. Known immunocompromised status, including but not limited to individuals who have&#xD;
             undergone organ transplantation, chemotherapy or radiotherapy within the past 12&#xD;
             months, who have clinically-significant leukopenia, who are positive for the human&#xD;
             immunodeficiency virus (HIV) , who are on potential immunosuppressants or whose immune&#xD;
             status makes the subject a poor candidate for clinical trial participation in the&#xD;
             opinion of the Investigator&#xD;
&#xD;
         24. History of malignancy within the past 5 years&#xD;
&#xD;
         25. Known active coagulopathy, or current upper gastro-intestinal bleeding conditions such&#xD;
             as ulcers, gastric varices, strictures, or congenital or acquired intestinal&#xD;
             telangiectasia&#xD;
&#xD;
         26. Subjects with active helicobacter pylori infection (Subjects may be enrolled if they&#xD;
             had history of h pylori infection and were successfully treated)&#xD;
&#xD;
         27. Known cases of anemia, thalassemia or conditions that affect RBC turnover such as&#xD;
             recent blood transfusion within 90 days&#xD;
&#xD;
         28. Use of anticoagulation therapy (such as warfarin, coumadin, NOAC) or anti platelet&#xD;
             agents (such as thienopyridine) which cannot be discontinued for 5-7 days or 2 drug&#xD;
             half-lives before and the procedure&#xD;
&#xD;
         29. Use of systemic glucocorticoids (excluding topical or ophthalmic application or&#xD;
             inhaled forms) for more than 10 consecutive days within 90 days prior to the Screening&#xD;
             Visit.&#xD;
&#xD;
         30. Use of drugs known to affect GI motility (e.g. Metoclopramide)&#xD;
&#xD;
         31. History of moderate to severe chronic kidney disease (CKD), with estimated glomerular&#xD;
             filtration rate (eGFR) &lt;45 ml/min/1.73m2 (estimated by Modification of Diet in Renal&#xD;
             Disease [MDRD]) or end stage renal failure or on dialysis&#xD;
&#xD;
         32. History of Myocardial Infarction, Stroke, or major event requiring hospitalization&#xD;
             within the last 3 months prior to screening&#xD;
&#xD;
         33. History of new or worsening signs or symptoms of CHD within the last 3 months&#xD;
&#xD;
         34. Known case of severe peripheral vascular disease&#xD;
&#xD;
         35. Known case of heart failure requiring pharmacologic therapy&#xD;
&#xD;
         36. Clinically significant ECG findings such as new clinically significant arrythmia or&#xD;
             conduction disturbances that increases risk and requires intervention as determined by&#xD;
             the investigator&#xD;
&#xD;
         37. Fasting triglyceride value of &gt;600 mg/dL (increases risk of pancreatitis)&#xD;
&#xD;
         38. Participating in a weight loss program and is currently not in the maintenance phase&#xD;
&#xD;
         39. General contraindications to deep or conscious sedation or general anesthesia or high&#xD;
             risk as determined by anesthesiologist (e.g. ASA score 4 or higher) or&#xD;
             contraindications to upper GI Endoscopy&#xD;
&#xD;
         40. History of any illicit alcohol or substance abuse&#xD;
&#xD;
         41. Use of weight loss medication such as Meridia, Xenical, or over the counterweight loss&#xD;
             medications or other prescribed medications used specifically for purpose of weight&#xD;
             loss.&#xD;
&#xD;
         42. Use of Dietary supplements or herbal preparations that may have unknown effects on&#xD;
             glycemic control, risk of bleeding&#xD;
&#xD;
         43. Participating in another ongoing clinical trial of an investigational drug or device&#xD;
&#xD;
         44. History of non-adherence to treatment in the previous 6 months, as determined by the&#xD;
             investigator based on patient history, HbA1C value and/or drug accountability.&#xD;
&#xD;
         45. Any other mental or physical condition which, in the opinion of the investigator,&#xD;
             makes the subject a poor candidate for clinical trial participation&#xD;
&#xD;
         46. Unwilling or unable to perform self-monitoring of blood glucose (SMBG), complete the&#xD;
             patient diary, or comply with study visits and other study procedures as required per&#xD;
             protocol.&#xD;
&#xD;
         47. Recovered from severe COVID 19 infection within 6 months or those who have persistent&#xD;
             long COVID-19 symptoms (i.e. they have not recovered for several weeks or months since&#xD;
             start of symptoms that were suggestive of COVID-19 irrespective if they are tested or&#xD;
             not.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah Hackett</last_name>
    <phone>781-902-8840</phone>
    <email>shackett@fractyl.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katrina Stanchfield</last_name>
      <email>Stanchfield.Katrina@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Rahul Pannala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kasey Sayer</last_name>
      <email>KSeyer@researchscrc.com</email>
    </contact>
    <investigator>
      <last_name>Georges Argoud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Swati Toppo</last_name>
      <phone>650-497-4151</phone>
      <email>stoppo@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Kwo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mills Peninsula Health Center</name>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <zip>94401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irina Nayberg</last_name>
      <email>nayberl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>David Klonoff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Prinz</last_name>
      <phone>203-785-5977</phone>
      <email>jacqueline.prinz@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Renata Belfort De Aguiar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niurka Colina</last_name>
      <phone>305-243-6405</phone>
      <email>Nxc610@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Unviersity</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candice Fulkerson</last_name>
      <phone>312-908-9002</phone>
      <email>candice.fulkerson@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Grazia Aleppo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Patrick, RN</last_name>
      <phone>317-278-0692</phone>
      <email>vpatrick@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Raj Vuppalanchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen James</last_name>
      <phone>502-852-2902</phone>
      <email>karen.james@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Prakash Mokshagundam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvia Haynes</last_name>
      <phone>504-988-4651</phone>
      <email>ehaynes@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Vivian Fonseca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Nicastro</last_name>
      <email>knicastro@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Vanita Aroda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Shea</last_name>
      <phone>617-632-1129</phone>
      <email>jmshea@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Michelle Lai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Neidert</last_name>
      <phone>734-615-0539</phone>
      <email>aneidert@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Elif Oral</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arb Teresa</last_name>
      <phone>314-747-1217</phone>
      <email>arbt@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Silverstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tracy Ostler</last_name>
      <phone>603-653-9033</phone>
      <email>Tracy.L.Ostler@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Sushela Chaidarun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JoAnne Lamacchia</last_name>
      <email>lamacchiaj@sjhmc.org</email>
    </contact>
    <investigator>
      <last_name>Sandra Gibiezaite</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Gastroenterology Associates</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gigi Ghiasian</last_name>
      <phone>201-410-6849</phone>
      <email>Ghoncheh.Ghiasian@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Akankasha Goyal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Speiser</last_name>
      <email>jus4008@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Rekha Kumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachelle Jacoby</last_name>
      <email>rachelle.jacoby@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Reshmi Srinath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>April Wittmann</last_name>
      <phone>919-668-1220</phone>
      <email>april.hawkins@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Rowell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Schnieder</last_name>
      <phone>216-444-1122</phone>
      <email>SCHNEIES@ccf.org</email>
    </contact>
    <investigator>
      <last_name>John Vargo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine Yerkes</last_name>
      <email>KATHERINE.YERKES@PENNMEDICINE.UPENN.EDU</email>
    </contact>
    <investigator>
      <last_name>Anastasia Amaro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor St. Luke's Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mercado</last_name>
      <phone>713-798-3606</phone>
      <email>Michael.Mercado@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Dimpi Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca Collen</last_name>
      <phone>804-628-4376</phone>
      <email>rebecca.collen@vcuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Arun Sanyal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Nguyen</last_name>
    </contact>
    <investigator>
      <last_name>Arthi Thiramulai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cami Handlan</last_name>
      <phone>304-293-6360</phone>
      <email>cami.handlan@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Adnan Haider</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires de Bruxelles Hopital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri Oger</last_name>
      <phone>+32 (0) 2555 5828</phone>
      <email>Dimitri.Oger@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Miriam Cnop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prete Bettina</last_name>
      <phone>+49 211 5660360 65</phone>
      <email>wdgz-studienzentrum@vkkd-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christiane Bott-Raffee</last_name>
      <email>bott@em.uni-frankfurt.de</email>
    </contact>
    <investigator>
      <last_name>Jorg Bojunga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole Nachtigall</last_name>
      <email>nicole.nachtigall@uniklinikfreiburg.de</email>
    </contact>
    <investigator>
      <last_name>Jochen Seufert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College Dublin</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camilo Menezes</last_name>
      <email>camilo.menezes@ucd.ie</email>
    </contact>
    <investigator>
      <last_name>Carel le Roux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Italy Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Caprodossi</last_name>
      <phone>+39 06 30155323</phone>
      <email>anna.caprodossi@policlinicogemelli.it</email>
    </contact>
    <investigator>
      <last_name>Geltrude Mingrone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universiteit Van Amsterdam Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjon Barlag</last_name>
      <phone>+31-20-5668713</phone>
      <email>m.j.barlag@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>Jacques Bergman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Caro Vega</last_name>
      <phone>+34 665 827 670</phone>
      <email>carovegajose@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pedro Pablo Garcia-Luna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathrin Husi</last_name>
      <phone>+41316325933</phone>
      <email>kathrin.husi@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Reiner Wiest</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sim Ratcliff</last_name>
      <email>simbisai.ratcliff@nhs.net</email>
    </contact>
    <investigator>
      <last_name>David Hopkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Telese, MD</last_name>
      <email>andrea.telese@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Adrea Pucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Revita System</keyword>
  <keyword>Duodenal Mucosal Resurfacing</keyword>
  <keyword>Insulin-Dependent Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

